CLVS Stock Price - Clovis Oncology Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

Open $32.34
Day Range 31.82 - 32.82
52 Week Range 31.19 - 86.26
Market Cap $1.7B
Shares Outstanding 52.65M
Public Float 49.13M
Beta 0.96
Rev. per Employee $211.46K
P/E Ratio n/a
EPS $-5.76
Yield n/a
Dividend n/a
Ex-Dividend Date n/a
Short Interest 8.28M 08/31/18
% of Float Shorted 16.85%
Average Volume 923.82K

5 Day	2.23%
1 Month	-7.60%
3 Month	-33.24%
YTD	-52.24%
1 Year	-58.66%

MarketWatch
Other Dow Jones

Clovis Oncology stock price target cut to $71 from $87 at J.P. Morgan

Sep. 21, 2018 at 7:55 a.m. ET
by Tomi Kilgore

SEC fines Clovis Oncology Inc., executives $20.8 million for lying about cancer drug effectiveness

Clovis Oncology Inc., will pay $20 million to settle charges by the Securities and Exchange Commission that it misled investors about the effectiveness of the company's developmental lung cancer drug, rociletinib, or Roci, according to an SEC press release. Its CEO Patrick Mahaffy, and Erle Mast, the company's former CFO, also settled charges. Over a four-month period starting in July 2015, the company and Mahaffy used its investor presentations, press releases, and SEC filings to inaccurately state that the drug was effective 60% of the time, meaning that in 60% of patients Roci caused targeted tumors to shrink, despite knowing actual results were much lower. Clovis raised approximately $298 million in a public stock offering in July 2015, but its stock price dropped by 70% in November 2015 after disclosing the true effectiveness rate, 28%. The company stopped development of the drug in May 2016. The defendants did not admit or deny the allegations. Mahaffy agreed to a $250,000 penalty and Mast agreed to pay a $100,000 penalty and to pay back $454,145, in proceeds from selling Clovis stock during the relevant period at the inflated prices.

Sep. 18, 2018 at 2:09 p.m. ET
by Francine McKenna

Why 2018 is a make-or-break year for pharma

Jan. 4, 2018 at 8:44 a.m. ET
by Emma Court

Republican tax bill makes big winners of Amgen, Gilead and other drugmakers

Dec. 20, 2017 at 8:27 a.m. ET
by Emma Court

Clovis stock drops 7.2% pre-market

Jul. 31, 2017 at 9:08 a.m. ET
by Emma Court

Bristol-Myers and Clovis will partner for cancer combination trials

Jul. 31, 2017 at 7:11 a.m. ET
by Emma Court

Bristol-Myers, Clovis collaboration includes phase 2 and phase 3 clinical trials

Jul. 31, 2017 at 7:02 a.m. ET
by Tomi Kilgore

Bristol-Myers Squibb and Clovis Oncology announce collaboration to evaluate Opdivo cancer treatment

Jul. 31, 2017 at 7:01 a.m. ET
by Tomi Kilgore

Clovis Oncology stock price target raised to $111 from $72 at J.P. Morgan

Jun. 20, 2017 at 7:30 a.m. ET
by Tomi Kilgore

Clovis Oncology to launch $250 mln stock offering

Jun. 19, 2017 at 4:13 p.m. ET
by Emma Court

Clovis Oncology to launch $250 mln stock offering

Jun. 19, 2017 at 4:08 p.m. ET
by Emma Court

Clovis Oncology stock surges 50% on positive late-stage cancer trial results

Jun. 19, 2017 at 8:51 a.m. ET
by Emma Court

Clovis Oncology's stock soars 49% premarket after positive phase 3 trial results

Jun. 19, 2017 at 8:36 a.m. ET
by Tomi Kilgore

Clovis Oncology stock price target raised to $72 from $58 at J.P. Morgan

May. 17, 2017 at 7:11 a.m. ET
by Tomi Kilgore

Clovis Oncology upgraded to overweight from neutral at J.P. Morgan

May. 17, 2017 at 7:10 a.m. ET
by Tomi Kilgore

Tesaro stock dives 7% after drug pricing snafu

Apr. 21, 2017 at 7:00 a.m. ET
by Emma Court

Morgan Stanley is bullish on gambling, bearish on jelly

Apr. 19, 2017 at 2:46 p.m. ET
by Ryan Vlastelica

These corporate ties will be on display at Scott Gottlieb’s FDA commissioner confirmation hearing today

Apr. 5, 2017 at 8:40 a.m. ET
by Emma Court

Tesaro won’t reveal price of its ovarian cancer drug. But it’ll likely be near $14,000 a month

Mar. 29, 2017 at 8:30 a.m. ET
by Emma Court

Opinion

3 tech and biotech stocks with momentum

Mar. 16, 2017 at 8:52 a.m. ET
by Harry Boxer

U.S. Stocks Climb as Tech Sector Bounces Back

Jun. 19, 2017 at 8:01 p.m. ET
on The Wall Street Journal

The Dark Side of Good News in Biotech

Jun. 19, 2017 at 11:41 a.m. ET
on The Wall Street Journal

Stocks to Watch: Apple, Amazon, Rice Energy, Valeant

Jun. 19, 2017 at 9:29 a.m. ET
on The Wall Street Journal

Tesaro Explores Sale

May. 31, 2017 at 3:57 p.m. ET
on The Wall Street Journal

Biotech M&A Trade Hits a Snag

Mar. 28, 2017 at 9:08 a.m. ET
on The Wall Street Journal

Resisting the Allure of Gilead

Mar. 16, 2017 at 10:32 a.m. ET
on Barron's

Big Pharma, Not Small Investors, Is Driving Biotech Values Now

Sep. 11, 2016 at 12:20 p.m. ET
on The Wall Street Journal

Would Gilead Pick Up Tesaro’s PARP?

Sep. 9, 2016 at 4:34 p.m. ET
on Barron's

New Drugs for Ovarian Cancer Patients

Sep. 5, 2016 at 10:00 a.m. ET
on The Wall Street Journal

Stocks to Watch: J.P. Morgan, Bank of America, Delphi Automotive, PulteGroup

Apr. 13, 2016 at 9:28 a.m. ET
on The Wall Street Journal

FDA Panel Opposes Approval of Clovis Lung-Cancer Treatment

Apr. 12, 2016 at 5:36 p.m. ET
on The Wall Street Journal

U.S. Stocks Rally, Led by Energy Sector

Nov. 16, 2015 at 8:40 p.m. ET
on The Wall Street Journal

AstraZeneca’s Lung-Cancer Drug Tagrisso Gets FDA’s Approval

Nov. 13, 2015 at 2:12 p.m. ET
on The Wall Street Journal

AstraZeneca Gets FDA Approval for Ovarian Cancer Drug

Dec. 19, 2014 at 5:12 p.m. ET
on The Wall Street Journal

Top Biotech Picks for Q2 Earnings

Jul. 22, 2014 at 11:07 a.m. ET
on Barron's

Stocks to Watch: Staples, TJX, Urban Outfitters

May. 20, 2014 at 9:41 a.m. ET
on The Wall Street Journal

Stocks to Watch: Citigroup, GameStop, Winnebago

Mar. 27, 2014 at 9:28 a.m. ET
on The Wall Street Journal

Intercept Pharmaceuticals: The Mother of All Momentum Stocks

Jan. 10, 2014 at 5:14 p.m. ET
on The Wall Street Journal

Health-Care Stocks: Where to Find Value

Nov. 12, 2013 at 6:08 a.m. ET
on Barron's

Stocks to Watch: Mako Surgical, Ascena, Oncothyreon

Sep. 25, 2013 at 9:37 a.m. ET
on The Wall Street Journal

Other News
Press Releases

Clovis Finally Faces the Music for Fraudulent Lung Cancer Drug Results

Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug.

Sep. 19, 2018 at 12:05 p.m. ET
on 247WallSt.com

Clovis and execs to pay $20M for misleading investors on rociletinib

Sep. 18, 2018 at 1:58 p.m. ET
on Seeking Alpha

Merrill Lynch Sees 4 Top Biotechs With Key Catalysts in 2018

With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.

Sep. 11, 2018 at 10:08 a.m. ET
on 247WallSt.com

Biotechs and biopharmas in the red

Sep. 6, 2018 at 12:43 p.m. ET
on Seeking Alpha

Your Cancer Highlight: Clovis Looks To Capture Deeper Relevance With Bristol-Myers Collab

Aug. 29, 2018 at 8:00 a.m. ET
on Seeking Alpha

A Look at Portola Pharmaceuticals’ Financial Position

In the second quarter, Portola Pharmaceuticals' (PTLA) cost of sales totaled $1.1 million.

Aug. 28, 2018 at 11:27 a.m. ET
on MarketRealist.com

Why Analysts Are Positive on Portola Pharmaceuticals in August

Portola Pharmaceuticals (PTLA) stock closed at $28.74 on August 27, which represents ~2.02% growth from its close of $28.17 on August 24.

Aug. 28, 2018 at 11:27 a.m. ET
on MarketRealist.com

Money flow stays positive in biotechs, XBI up 6% since last week

Aug. 27, 2018 at 11:39 a.m. ET
on Seeking Alpha

Clovis’s Rubraca Keeps Investors Interested

In this series, we'll explore Clovis's financials, analysts’ views on its stock, its significant pipeline developments, and its valuation metrics.

Aug. 24, 2018 at 4:46 a.m. ET
on MarketRealist.com

Analyzing Clovis Oncology’s Financial Performance

Clovis Oncology (CLVS) generated product revenue from its sales of Rubraca of $23.76 million in the second quarter.

Aug. 24, 2018 at 4:49 a.m. ET
on MarketRealist.com

What Does Clovis Oncology’s Valuation Trend Indicate?

The share price of Clovis Oncology (CLVS) has been on a downward trajectory so far in 2018.

Aug. 24, 2018 at 4:52 a.m. ET
on MarketRealist.com

Exact Sciences: Why the Stock Price Is Soaring

On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.

Aug. 22, 2018 at 12:12 p.m. ET
on MarketRealist.com

Analysts’ Expectations for Tesaro and Its Peers in August

Of the 18 analysts covering Tesaro in August, 11 of them have given the stock a "buy" or higher rating, and seven have given it a "hold."

Aug. 16, 2018 at 3:15 p.m. ET
on MarketRealist.com

Here’s What Tesaro’s Valuation Trend Indicates

Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

Aug. 15, 2018 at 2:39 p.m. ET
on MarketRealist.com

Copernicus Capital Management, LLC Buys CVS Health Corp, Hologic Inc, Integra Lifesciences ...

Copernicus Capital Management, LLC Buys CVS Health Corp, Hologic Inc, Integra Lifesciences Holdings Corp, Sells Cigna Corp, Biogen Inc, Gilead Sciences Inc

Aug. 15, 2018 at 3:38 p.m. ET
on GuruFocus.com

Puma Biotechnology: Recent Developments and Recommendations

In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s Nerlynx.

Aug. 10, 2018 at 11:00 a.m. ET
on MarketRealist.com

How Puma Biotechnology Performed in Q2 2018

Puma Biotechnology released its second-quarter earnings results on August 9. The company generated revenue of $50.8 million in the quarter.

Aug. 10, 2018 at 11:00 a.m. ET
on MarketRealist.com

Here’s How Exelixis Is Financially Positioned Now

Exelixis (EXEL) reported its Q2 2018 results on August 1. It had net revenues of $186.1 million compared to $99 million in Q2 2017.

Aug. 9, 2018 at 11:28 a.m. ET
on MarketRealist.com

Analyst Recommendations for Exelixis in August

In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.

Aug. 9, 2018 at 11:28 a.m. ET
on MarketRealist.com

3 Things In Biotech, August 9: Clovis Looks Forward In Ovarian Cancer

Aug. 9, 2018 at 9:53 a.m. ET
on Seeking Alpha

United States : Biopharmaceutical Company, Executives Charged With Misleading Investors About Cancer Drug

Sep. 19, 2018 at 7:36 p.m. ET
on Euclid Tenders Info

Biopharmaceutical Company, Executives Charged With Misleading Investors About Cancer Drug

Sep. 18, 2018 at 1:55 p.m. ET
on Newsfile Corp

Clovis Oncology to Present at the Morgan Stanley Global Healthcare Conference

Sep. 6, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Ovarian Cancer Drugs Market Expected To Be Worth by 2016 - 2022

Sep. 3, 2018 at 9:51 a.m. ET
on Heraldkeeper

Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences -- Renewed Outlook, Key Drivers of Growth

Aug. 27, 2018 at 7:45 a.m. ET
on GlobeNewswire

Ovarian Cancer Drugs Market is Expected to Exceed by 2016 - 2022

Aug. 20, 2018 at 11:55 a.m. ET
on Heraldkeeper

IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

Aug. 15, 2018 at 9:00 a.m. ET
on PR Newswire - PRF

Ovarian Cancer Drugs Market is Determined to Cross by 2016 - 2022

Aug. 14, 2018 at 7:44 a.m. ET
on Heraldkeeper

Pancreatic Cancer Market 2018 Expected to Reach Highest Growth Line at 8.1% CAGR by 2023 | Market Research Future

Aug. 13, 2018 at 3:48 a.m. ET
on Heraldkeeper

Ovarian Cancer Drugs Market is Expected to Exceed by 2016 - 2022

Aug. 8, 2018 at 11:00 a.m. ET
on Heraldkeeper

Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

Aug. 8, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Cancer API Market 2018 Size, Growth Overview, Worldwide Segmentation Mega Trends by 2023

Aug. 6, 2018 at 4:21 a.m. ET
on Heraldkeeper

Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1

Jul. 18, 2018 at 8:00 a.m. ET
on BusinessWire - BZX

Ovarian Cancer Drugs Market Size Will Exceed by 2016 – 2022

Jul. 10, 2018 at 8:21 a.m. ET
on Heraldkeeper

Free Technical Research on Clovis Oncology and Three More Biotech Equities

Jul. 9, 2018 at 10:46 a.m. ET
on ACCESSWIRE

Today's Research Reports on Trending Tickers: Clovis Oncology and Global Blood Therapeutics

Jul. 4, 2018 at 8:04 a.m. ET
on ACCESSWIRE

Pancreatic Cancer Market Size is Projected to be Around US$ 13 Billion By 2023

Jun. 26, 2018 at 3:10 p.m. ET
on Heraldkeeper

Analysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology -- Research Highlights Growth, Revenue, and Consolidated Results

Analysis: Positioning to Benefit within PBF Energy, Callaway Golf, Total System Services, Comcast, The Cheesecake Factory, and Clovis Oncology -- Research Highlights Growth, Revenue, and Consolidated Results

Jun. 26, 2018 at 7:50 a.m. ET
on GlobeNewswire

Today's Research Reports on Trending Tickers: Clovis Oncology and Cronos Group

Jun. 21, 2018 at 8:26 a.m. ET
on ACCESSWIRE

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022

Jun. 18, 2018 at 10:05 a.m. ET
on PR Newswire - PRF

Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 10 Full Ratings

Benzinga's Top Upgrades, Downgrades For February 22, 2018

Feb. 22, 2018 at 9:58 a.m. ET
on Benzinga.com

Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market

Nov. 8, 2017 at 5:11 p.m. ET
on Benzinga.com

Benzinga's Top Upgrades, Downgrades For October 23, 2017

Oct. 23, 2017 at 9:19 a.m. ET
on Benzinga.com

Name	Chg %	Market Cap
BioMarin Pharmaceutical Inc.	0.63%	$17.72B
Celgene Corp.	1.05%	$61.46B
AstraZeneca PLC ADR	1.13%	$93.32B
Johnson & Johnson	1.08%	$376.82B
Eli Lilly & Co.	0.31%	$113.56B

Competitor Data Provided By

DJIA F	26,771	44	0.16%
S&P F	2,942.00	2.50	0.09%
NASDAQ F	7,620.00	11.25	0.15%
Gold	1,200.80	-10.50	-0.87%
Silver	14.32	0.015	0.10%
Crude Oil	70.85	0.53	0.75%

Clovis Oncology Inc.

$ 32.48

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers

Clovis Oncology stock price target cut to $71 from $87 at J.P. Morgan

Clovis stock drops 7.2% pre-market

Bristol-Myers, Clovis collaboration includes phase 2 and phase 3 clinical trials

Bristol-Myers Squibb and Clovis Oncology announce collaboration to evaluate Opdivo cancer treatment

Clovis Oncology stock price target raised to $111 from $72 at J.P. Morgan

Clovis Oncology to launch $250 mln stock offering

Clovis Oncology's stock soars 49% premarket after positive phase 3 trial results

Clovis Oncology stock price target raised to $72 from $58 at J.P. Morgan

Clovis Oncology upgraded to overweight from neutral at J.P. Morgan

Stocks

Columns

Authors

Topics

^$ 32.48